nonfatal

US

・

UK

A1

adj.AdjectiveNot bringing death

Video subtitles

After a median follow-up of 40.6 months, the incidence of a primary endpoint event, a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, was significantly lower in the bempedoic acid group, at 11.7%, than in the placebo group, at 13.3%.
After a median follow-up of 40.6 months, the incidence of a primary endpoint event, a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, was significantly lower in the bempedoic acid group, at 11.7%, than in the placebo group, at 13.3%.
A key secondary efficacy endpoint event, a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurred significantly less often in the bempedoic acid group.
A key secondary efficacy endpoint event, a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurred significantly less often in the bempedoic acid group.

and I'm certainly not telling them to start smoking, it simply becomes harder and harder to contextualize a 10% versus an 8% 10-year risk of nonfatal MI.
and I'm certainly not telling them to start smoking, it simply becomes harder and harder to contextualize a 10% versus an 8% 10-year risk of nonfatal MI.

US

・

UK

A1

adj.AdjectiveNot bringing death

After a median follow-up of 40.6 months, the incidence of a primary endpoint event, a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, was significantly lower in the bempedoic acid group, at 11.7%, than in the placebo group, at 13.3%.
After a median follow-up of 40.6 months, the incidence of a primary endpoint event, a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, was significantly lower in the bempedoic acid group, at 11.7%, than in the placebo group, at 13.3%.
A key secondary efficacy endpoint event, a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurred significantly less often in the bempedoic acid group.
A key secondary efficacy endpoint event, a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurred significantly less often in the bempedoic acid group.

and I'm certainly not telling them to start smoking, it simply becomes harder and harder to contextualize a 10% versus an 8% 10-year risk of nonfatal MI.
and I'm certainly not telling them to start smoking, it simply becomes harder and harder to contextualize a 10% versus an 8% 10-year risk of nonfatal MI.